Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic

  • Search Hotels in Burlingame

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amgen (NQ: AMGN )

294.53 +4.63 (+1.60%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amgen

< Previous 1 2
...
15 16 17 18 19 20 21 22 23
...
47 48 Next >
Looking Into Amgen's Recent Short Interest
Via Benzinga
If You Had Invested $5,000 in Amgen in 2013, This Is How Much You Would Have Today
The pharmaceutical company has significantly enriched shareholders over the past 10 years. 
Via The Motley Fool
Amgen Raises FY23 Outlook, Discloses Brief Readout From Tarlatamab Lung Cancer, Lumakras Colorectal Cancer Studies
Amgen Inc AMGN reported Q2 FY23 sales of $6.99 billion, up 7% Y/Y, beating the consensus of $6.63 billion. 
Via Benzinga
Amgen Beats Expectations, Raises Outlook With Horizon Takeover In The Wings
The massive biotech company also beat second-quarter expectations Thursday. 
Via Investor's Business Daily
Why Is Regeneron Pharmaceuticals Moving Higher Today?
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) earned second-quarter adjusted EPS of $10.24, up 5% Y/Y, beating the $9.92 Stre 
Via Benzinga
3 Dividend Stocks That Hiked Payouts by 60% in Just 5 Years
Can these stocks keep the rate hikes coming? 
Via The Motley Fool
Mind Science Targeting Big Brains and Portfolios
Via AB Newswire
Looking At Amgen's Recent Unusual Options Activity
Via Benzinga
Check Out What Whales Are Doing With AMGN
Via Benzinga
2 Cheap High-Yield Dividend Stocks to Buy Now
These two pharma stocks are top-notch passive income vehicles. 
Via The Motley Fool
US Stock Futures Dip As Apple, Amazon Earnings Loom: Analyst Warns Of 'Perfectly Normal' 5% Pullback This Month
Stocks appear to be entrenched in an August swoon and it remains to be seen if big tech earnings provide a boost. 
Via Benzinga
Amgen To Report Q2 Earnings: Here's What To Expect
Amgen will report second-quarter 2023 results on Aug. 3, after the market close. 
Via Talk Markets
The Dow Breaks 13-Day Winning Streak, Fed Raises Interest Rates To 2001 Levels And AI Is The Buzzword For Big Tech Earnings: The Week In The Markets
Via Benzinga
(AMGN) - Analyzing Amgen's Short Interest
Via Benzinga
Is Amgen's Dividend Safe?
Despite multiple headwinds, the biotech's dividend appears to be a safe play for income investors. 
Via The Motley Fool
Rising Stars, Falling Trends: July's Industry ETF Winners And Losers
Via Benzinga
Reata's Acquisition Fits Biogen's Strategy Despite High Cost: Analyst Says High Level Regulatory Scrutiny Not Anticipated
Earlier today, Biogen Inc (NASDAQ: BIIB) agreed to acquire Reata Pharmaceuticals Inc (NASDAQ: RETA) for $172.50 per share in cash, reflecting an enterprise value of  
Via Benzinga
3 Things About Johnson & Johnson Every Smart Investor Knows
The company has been a strong value stock but faces big changes this year. 
Via The Motley Fool
INVESTIGATION ALERT: Scott+Scott Attorneys at Law LLP Investigates Amgen Inc’s Directors and Officers for Breach of Fiduciary Duties – AMGN
From Scott+Scott Attorneys at Law LLP
Via Business Wire
AbbVie Earnings, Revenue Fall Less Than Expected
Drug maker AbbVie reported Q2 profit and sales that fell from a year earlier but topped expectations. AbbVie stock rose. 
Via Investor's Business Daily
AbbVie's Skyrizi Achieves Superiority Versus Amgen's Drug In Head-to-Head Study In Moderate Plaque Psoriasis
AbbVie Inc (NYSE: ABBV) announced that the British Journal of Dermatology published results from the head-to-head Phase 4 IMMpulse study that evaluated the efficacy and safety of Skyrizi (risankizumab)... 
Via Benzinga
Seven Humira Biosimilars: Increased Competition In Arthritis Drug Market Sparks Need For Reform Of Drug Pricing Intermediaries
Seven pharmaceutical companies recently launched their biosimilars of AbbVie Inc's (NYSE: ABBV) top-selling  
Via Benzinga
Lilly Shares Up On Versanis Deal Amid Weight-Loss Drug Gold Rush
A bid to acquire Versanis boosts Eli Lilly & Co. by 2.80% in the past week, as the competition to develop the most effective weight-loss drug intensifies. 
Via MarketBeat
The 3 Most Undervalued Pharma Stocks to Buy Now: July 2023
Trading below a 15 forward price-to-earnings, these undervalued pharma stocks offer opportunities in an overbought market. 
Via InvestorPlace
Tesla On Tap: "Mega-cap" Reporting Season Gets Underway After Close With EV Giant's Earnings
(Wednesday market open) Major indexes ride into Tesla’s (NASDAQ: TSLA) earnings later today on a long winning streak that carried stocks to new 15-month highs yesterday. Hopes for an economic “soft... 
Via Benzinga
Softbank, Amgen-Backed Neumora Therapeutics Unveils Plans For Three Phase 3 Studies For Major Depressive Disorder
Neumora Therapeutics unveiled plans for three late-stage studies for its major depre 
Via Benzinga
3 Biotech Stocks for Getting Rich in 2023
These 3 biotech stocks have seen stable or growing revenue this year. This makes them companies to keep on your watchlist. 
Via InvestorPlace
Venturing Beyond The Magic Kingdom: Former Disney CFO And Fortune 500 Veteran Takes The Reins At Lucy Scientific
As of July 13, Lucy Scientific Discovery (NASDAQ: LSDI) has a new principal. 
Via Benzinga
2 Best Biotech Stocks to Buy Right Now
These two pharmaceutical titans look like convincing buys for income investors. 
Via The Motley Fool
The Blazing Weight-Loss Drug Battle: Can Anyone Unseat Undisputed Leaders Novo Nordisk And Lilly?
An overweight world is hungry for new treatments. For now, two companies own the market. 
Via Investor's Business Daily
< Previous 1 2
...
15 16 17 18 19 20 21 22 23
...
47 48 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Burlingame.com & California Media Partners, LLC. All rights reserved.